» Articles » PMID: 38132121

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression

Overview
Journal Cells
Publisher MDPI
Date 2023 Dec 22
PMID 38132121
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, there has been a growing interest in the relationship between microorganisms in the surrounding environment and cancer cells. While the tumor microenvironment predominantly comprises cancer cells, stromal cells, and immune cells, emerging research highlights the significant contributions of microbial cells to tumor development and progression. Although the impact of the gut microbiome on treatment response in lung cancer is well established, recent investigations indicate complex roles of lung microbiota in lung cancer. This article focuses on recent findings on the human lung microbiome and its impacts in cancer development and progression. We delve into the characteristics of the lung microbiome and its influence on lung cancer development. Additionally, we explore the characteristics of the intratumoral microbiome, the metabolic interactions between lung tumor cells, and how microorganism-produced metabolites can contribute to cancer progression. Furthermore, we provide a comprehensive review of the current literature on the lung microbiome and its implications for the metastatic potential of tumor cells. Additionally, this review discusses the potential for therapeutic modulation of the microbiome to establish lung cancer prevention strategies and optimize lung cancer treatment.

Citing Articles

Exploring the prognostic role of microbial and genetic markers in lung squamous cell carcinoma.

Yang F, Jia X, Ma Z, Liu S, Liu C, Chen D Sci Rep. 2025; 15(1):4499.

PMID: 39915534 PMC: 11802751. DOI: 10.1038/s41598-025-88120-2.


Classification of NSCLC subtypes using lung microbiome from resected tissue based on machine learning methods.

Kashyap P, Raj K, Sharma J, Dutt N, Yadav P NPJ Syst Biol Appl. 2025; 11(1):11.

PMID: 39824879 PMC: 11742043. DOI: 10.1038/s41540-025-00491-4.


Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression.

Park Y, Choi S, Cha Y, Yoon H, Son Y J Microbiol. 2024; 62(9):709-725.

PMID: 39240507 DOI: 10.1007/s12275-024-00167-4.


Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).

Del Giudice T, Staropoli N, Tassone P, Tagliaferri P, Barbieri V Cancers (Basel). 2024; 16(10).

PMID: 38791885 PMC: 11120070. DOI: 10.3390/cancers16101806.

References
1.
Mozaffari S, Salehi A, Mousavi E, Zaman B, Eslambol Nassaj A, Ebrahimzadeh F . SARS-CoV-2-associated gut microbiome alteration; A new contributor to colorectal cancer pathogenesis. Pathol Res Pract. 2022; 239:154131. PMC: 9477615. DOI: 10.1016/j.prp.2022.154131. View

2.
Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F . The clinical role of the TME in solid cancer. Br J Cancer. 2018; 120(1):45-53. PMC: 6325164. DOI: 10.1038/s41416-018-0327-z. View

3.
Pavlides S, Vera I, Gandara R, Sneddon S, Pestell R, Mercier I . Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal. 2011; 16(11):1264-84. PMC: 3324816. DOI: 10.1089/ars.2011.4243. View

4.
Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P . Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2):189-210. PMC: 4663145. DOI: 10.1016/j.bbcan.2015.08.002. View

5.
Chen J, Li T, Ye C, Zhong J, Huang J, Ke Y . The Lung Microbiome: A New Frontier for Lung and Brain Disease. Int J Mol Sci. 2023; 24(3). PMC: 9916971. DOI: 10.3390/ijms24032170. View